Many medical manufacturers perceive the value of incorporating patients’ experiences and outcomes in R&D processes as a way to align research efforts with patients’ needs. To ensure that appropriate frameworks and metrics are available for such patient-focused R&D, manufacturers have developed internally facing and externally facing metrics to quantify the impact of patient engagement (PE) and have devised tools to calculate appropriate renumeration for patients’ R&D participation. Among pharma researchers, collaborative industries, and investors, interest is emerging as to how manufacturers’ ESG goals can align with PE, and how ESG metrics could be used to quantify the impact of investment dollars and PE-related metrics. This discussion will explore the perspectives of biotech and pharma researchers, their research collaborators, and investors on the perceived value of PE efforts, approaches to quantify the value of such efforts, and the utility of emerging R&D frameworks.